Celgene

Bristol's Celgene buyout 'more important' given drug pricing pressure, CEO says
Bristol's Celgene buyout 'more important' given drug pricing pressure, CEO says
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
drug pricing
Giovanni Caforio
Flag link:
Why wait? Celgene restructures a big Jounce pact — zeroing in on new I/O pathway with $530M deal and bumping ICOS
Why wait? Celgene restructures a big Jounce pact — zeroing in on new I/O pathway with $530M deal and bumping ICOS
Endpoints
Celgene
Jounce Therapeutics
JTX-8064
macrophages
Flag link:
FDA Approves First Treatment for Oral Ulcers Associated with Rare Inflammatory Disease
FDA Approves First Treatment for Oral Ulcers Associated with Rare Inflammatory Disease
BioSpace
Otzela
Celgene
FDA
Behcet's disease
Flag link:
Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect
Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect
Marketwatch
Celgene
Biogen
AbbVie
Bristol-Myers Squibb
earnings
Flag link:
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
Investors Business Daily
Bristol-Myers Squibb
Celgene
M&A
Otezla
Gilead Sciences
Amgen
Regeneron
Eli Lilly
JNJ
Flag link:
Celgene bags option on Nimbus' anticancer HPK1 inhibitor
Celgene bags option on Nimbus' anticancer HPK1 inhibitor
Fierce Biotech
Celgene
Nimbus Therapeutics
HPK1 inhibitors
Flag link:
Why Bristol-Myers Squibb Stock Plunged in the First Half of 2019
Why Bristol-Myers Squibb Stock Plunged in the First Half of 2019
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Flag link:
FDA Action Alert: Karyopharm, Merck and Celgene
FDA Action Alert: Karyopharm, Merck and Celgene
BioSpace
FDA
Karyopharm
Selinexor
Merck
relebactam
Celgene
Otezla
Flag link:
The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)
The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)
Yahoo/Motley Fool
Bristol-Myers Squibb
Celgene
M&A
BeiGene
tislelizumab
Otezla
Flag link:
Bristol-Myers Squibb: Losing Otezla Might Be Challenging
Bristol-Myers Squibb: Losing Otezla Might Be Challenging
Market Realist
Bristol-Myers Squibb
Celgene
M&A
Otezla
Flag link:
FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
Endpoints
Bristol-Myers Squibb
Opdivo
Otezla
M&A
FTC
Celgene
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?
What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Meet the Top Ten Drugs of 2024 (Maybe)
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
Flag link:
As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup
As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup
Endpoints
BeiGene
Bristol-Myers Squibb
Celgene
Opdivo
Flag link:
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Flag link:
Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO
Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO
BioCentury
Grail
diagnostics
Juno Therapeutics
Celgene
Flag link:
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Flag link:
BMS reveals its post-Celgene takeover management team
BMS reveals its post-Celgene takeover management team
Pharmaforum
Bristol-Myers Squibb
Celgene
M&A
Flag link:

Pages